Startup · $2.4m raised · Healthcare
Melbourne, VIC
Every investor coverage indicates participated in a round Hatchtech raised.
| Investor | Rounds | Invested |
|---|---|---|
| Uniseed | Grant | - |
| University of Melbourne Endowment | Grant | - |
Companies Hatchtech acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr John Kurek | GBS Ventures | |
| Dr Paul Kelly | Chairman (former) | OneVentures portfolio, GBS Ventures |
| Dr Paul MacLeman | Chief Executive Officer (former) | GBS Ventures (Tue 21 Apr 2009), GBS Ventures (Mon 21 May 2007) |
| Dr Ross Macdonald | Non-executive Director (former) | GBS Ventures |
| Dr Stewart Washer | Chairman (former) | GBS Ventures (Tue 21 Apr 2009), GBS Ventures (Tue 18 Dec 2007) |
| Hugh Alsop | CEO (former) | GBS Ventures (Mon 3 Aug 2020), OneVentures portfolio, GBS Ventures (Thu 8 Sep 2016), GBS Ventures (Thu 12 Dec 2013), GBS Ventures (Thu 31 Oct 2013) |
| Professor Vern Bowles | Founder and CSO (former) | GBS Ventures, OneVentures portfolio |
Stories naming Hatchtech. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia
Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.
Biotech Hatchtech announced chief executive Paul MacLeman is resigning to lead another listed biotech; chairman Stewart Washer praised the head lice product's progress toward Phase II trials as a replacement is sought.
Hatchtech, an insect-control biotech, has appointed Dr Stewart Washer as chairman, citing his record founding biotech and agribusiness companies and taking Phylogica through an IPO.
A trial of Hatchtech's DeOvoT head lice treatment found no side effects in its first human testing, with an FDA filing and a second-phase study planned and crop-spray work ongoing.
Melbourne biotech Hatchtech received two $10,000 Australian commercialisation prizes and had recently drawn down extra funding to sit alongside its $2.4 million government grant for its head lice treatment.